Nicole Sweeny - 26 Jun 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship
Director
Issuer ticker
MNPR
Reported as of
26 Jun 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Jun 2026, 16:57:59 UTC
Prior SEC filing
30 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Quan Vu, Attorney-in-fact

Key filing fact

Nicole Sweeny filed Form 4 for Monopar Therapeutics (MNPR) on 30 Jun 2026.

Key facts

  • This page summarizes Nicole Sweeny's Form 4 filing for Monopar Therapeutics (MNPR).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 30 Jun 2026, 16:57.

Change

  • Previous filing in this sequence was filed on 30 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001827505 Primary reporting owner

Sweeny Nicole

Relationship
Director
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature
/s/ Quan Vu, Attorney-in-fact
Signature date
30 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Options

Award

Transaction value
Shares
+1,284
Change %
Price
$0.000000*
Shares after
1,284
Date
26 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,284
Exercise price
$87.68
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Options vest 50% on September 30, 2026, and 50% on December 31, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .